Der er begrænset effekt af interferonbeta til behandling af sekundær progressiv multipel sklerose - En gennemgang af et Cochranereview

Ugeskrift for Laeger

Volumn 175, Issue 19, 2013, Pages 1342-1344

  Schreiber, Karen ^a   Voldsgaard, Ana ^a   Sørensen, Per Soelberg ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; IMMUNOLOGIC FACTOR;

ARTICLE; HUMAN; LITERATURE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT;

HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; OUTCOME ASSESSMENT (HEALTH CARE); REVIEW LITERATURE AS TOPIC;

EID: 84878624267     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. La Mantia L, Vacchi L, Di Pietrantonj C et al. Interferon beta for secondary progressive multiple sclerosis. Review. The Cochrane Library 2012;1:CD005181.
2. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-7.
3. SPECTRIMS. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001;56:1496-504.
4. Cohen JA, Cutter GR, Fischer JS et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002;59:679-87.
5. The North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled. Neurology 2004;63:1788-95.
6. Andersen O, Elovaara I, Farkkila M et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2004;75:706-10.
7. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006;129:606-16.
8. Behandlingsvejledning for terapiområdet sklerose. København: Rådet for Anvendelse af Dyr Sygehusmedicin, 2011.